Alliance to Generate Antibodies to Drug Targets
By Biotechdaily staff writers
Posted on 20 Aug 2002
antibodies to drug targets has been announced by Biosite Inc. (San Diego, CA, USA; www.biosite.com) and MedImmune, Inc. (Gaithersburg, MD, USA; www.medimmune.com). Biosite will use its Omniclonal phage display technology to generate high-affinity antibodies to drug targets provided by MedImmune, whose research is focused on infectious disease, autoimmune disease, and cancer.Posted on 20 Aug 2002
Under the agreement, MedImmune has agreed to provide Biosite with targets for a period of up to three years. In addition to certain diagnostic rights, Biosite will receive development fees upon delivery of target-specific antibodies to MedImmune and royalties from any products resulting from MedImmune's research.
"As a leading biotechnology company, MedImmune fits the profile of an exemplary partner,” said Gunars Valkirs, Ph.D., vice president, Biosite Discovery. "By providing a supply of high affinity antibodies that can be used to identify and validate targets, we hope to accelerate MedImmune's research.”
Related Links:
Biosite
MedImmune
Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
